| CNTX |
Context Therapeutics Inc. |
Common Stock, par value $0.001 per share |
9.9% |
$8,913,522 |
+$72,083 |
9,200,580 |
+0.82% |
Avidity Partners Management LP |
30 Sep 2025 |
| SCYX |
Scynexis, Inc. |
Common Stock, par value $0.001 per share |
9.9% |
$3,477,903 |
+$234,763 |
4,516,757 |
+7.2% |
Avidity Private Master Fund I LP |
30 Sep 2025 |
| SYRS |
Syros Pharmaceuticals, Inc. |
Common Stock, $0.001 par value |
7.6% |
$61,441 |
|
2,048,020 |
|
Avidity Partners Management LP |
31 Dec 2024 |
| KZR |
Kezar Life Sciences, Inc. |
Common Stock, par value $0.001 per share |
6.9% |
$397,054 |
|
502,600 |
|
Avidity Partners Management LP |
31 Dec 2024 |
| DNTH |
Dianthus Therapeutics, Inc. |
Common Stock, $0.001 par value |
4.9% |
$70,995,168 |
-$43,010,234 |
2,104,184 |
-38% |
Avidity Partners Management LP |
17 Nov 2025 |
| IMUX |
Immunic, Inc. |
Common Stock, $0.0001 par value |
4.8% |
$4,143,001 |
-$807,898 |
4,699,411 |
-16% |
Avidity Partners Management LP |
30 Sep 2025 |
| CATX |
Perspective Therapeutics, Inc. |
Common Stock, $0.001 par value |
4.2% |
$6,903,688 |
|
2,841,024 |
|
Avidity Partners Management LP |
31 Dec 2024 |
| KZR |
Kezar Life Sciences, Inc. |
Common Stock, par value $0.001 per share |
0% |
$0 |
|
0 |
|
Avidity Partners Management LP |
30 Sep 2025 |